Sep 11, 2026 04:30PM
Mar 27, 2026 05:00PM
Feb 19, 2026 07:30AM
Feb 19, 2026 07:30AM
Sep 12, 2025 08:30AM
Jul 15, 2025 04:30PM
Jul 15, 2025 04:30PM ADR Ratio Change
Apr 11, 2025 08:30AM
Nov 21, 2024 07:35AM
Oct 17, 2024 07:34AM
Oct 17, 2024 07:30AM
Oct 15, 2024 04:15PM
Oct 15, 2024 04:15PM
Oct 15, 2024 04:15PM Biodexa Announces Successful Appeal of Nasdaq Delisting
Sep 26, 2024 08:30AM
Sep 19, 2024 04:30PM
Sep 19, 2024 04:30PM
Sep 16, 2024 08:32AM
Sep 16, 2024 08:30AM
Aug 30, 2024 04:30PM
Jul 23, 2024 08:30AM Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
Jul 19, 2024 08:31AM
Jul 19, 2024 08:30AM
Jul 11, 2024 08:32AM
Jul 11, 2024 08:30AM
Jul 2, 2024 08:30AM
Jun 24, 2024 08:30AM
Jun 13, 2024 09:35AM Results of Annual General Meeting
Jun 10, 2024 08:30AM
May 22, 2024 08:30AM
May 21, 2024 08:30AM
May 9, 2024 08:00AM
Apr 30, 2024 11:51AM
Apr 26, 2024 08:31AM
Apr 26, 2024 08:30AM Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Apr 26, 2024 08:30AM
Apr 19, 2024 08:00AM
Mar 28, 2024 08:18AM
Mar 28, 2024 08:15AM
Dec 21, 2023 04:00PM
Nov 27, 2023 09:00AM
Nov 27, 2023 09:00AM Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
Sep 29, 2023 04:30PM
Apr 28, 2023 04:30PM

1,194,569 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All